CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 07 2022
Historique:
received: 18 03 2022
accepted: 18 07 2022
entrez: 29 7 2022
pubmed: 30 7 2022
medline: 3 8 2022
Statut: epublish

Résumé

Anticancer combination therapy has been developed to increase efficacy by enhancing synergy. Patient-derived xenografts (PDXs) have emerged as reliable preclinical models to develop effective treatments in translational cancer research. However, most PDX combination study designs focus on single dose levels, and dose-response surface models are not appropriate for testing synergism. We propose a comprehensive statistical framework to assess joint action of drug combinations from PDX tumor growth curve data. We provide various metrics and robust statistical inference procedures that locally (at a fixed time) and globally (across time) access combination effects under classical drug interaction models. Integrating genomic and pharmacological profiles in non-small-cell lung cancer (NSCLC), we have shown the utilities of combPDX in discovering effective therapeutic combinations and relevant biological mechanisms. We provide an interactive web server, combPDX ( https://licaih.shinyapps.io/CombPDX/ ), to analyze PDX tumor growth curve data and perform power analyses.

Identifiants

pubmed: 35906256
doi: 10.1038/s41598-022-16933-6
pii: 10.1038/s41598-022-16933-6
pmc: PMC9338066
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12984

Subventions

Organisme : NCI NIH HHS
ID : U54 CA224065
Pays : United States
Organisme : NIH HHS
ID : 2P50CA070907-21A1
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA244845
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA078778
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NIH HHS
ID : 5U54CA224065-04
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Chin J Cancer. 2011 Jan;30(1):62-8
pubmed: 21192845
Cancer Lett. 2015 Feb 1;357(1):179-185
pubmed: 25444907
Front Pharmacol. 2014 May 28;5:118
pubmed: 24904421
Bioinformatics. 2017 Aug 01;33(15):2413-2415
pubmed: 28379339
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Oncol Rep. 2014 Mar;31(3):1219-24
pubmed: 24452392
Front Pharmacol. 2017 Apr 20;8:158
pubmed: 28473769
Pediatr Blood Cancer. 2007 Dec;49(7):928-40
pubmed: 17066459
Nucleic Acids Res. 2019 Jan 8;47(D1):D1073-D1079
pubmed: 30535239
Bioinformatics. 2016 Sep 15;32(18):2866-8
pubmed: 27153664
Proc Natl Acad Sci U S A. 1932 Jan;18(1):1-8
pubmed: 16577417
Mol Syst Biol. 2007;3:80
pubmed: 17332758
J Med Chem. 2014 Feb 27;57(4):1454-72
pubmed: 24456472
Ann Oncol. 2017 Oct 01;28(10):2595-2605
pubmed: 28945830
Am J Respir Crit Care Med. 2011 Jan 15;183(2):152-6
pubmed: 21242594
PLoS One. 2019 Nov 25;14(11):e0224137
pubmed: 31765385
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2349-54
pubmed: 24469833
Nat Commun. 2020 Jun 10;11(1):2935
pubmed: 32523045
Nat Med. 2015 Nov;21(11):1318-25
pubmed: 26479923
Pharmacol Rev. 1989 Jun;41(2):93-141
pubmed: 2692037
Ann Oncol. 2017 Mar 1;28(3):597-603
pubmed: 27998968
J Mol Cell Cardiol. 1998 Apr;30(4):723-31
pubmed: 9602421
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Trends Microbiol. 2016 Nov;24(11):862-871
pubmed: 27430191
Am J Cancer Res. 2020 Dec 01;10(12):4464-4475
pubmed: 33415011
CPT Pharmacometrics Syst Pharmacol. 2014 May 07;3:e113
pubmed: 24806032
Cancer. 2019 Nov 1;125(21):3738-3748
pubmed: 31287557
Cancer Res Treat. 2018 Jan;50(1):1-10
pubmed: 28903551
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Pharmacol Res Perspect. 2015 Jun;3(3):e00149
pubmed: 26171228
Pharmacol Rev. 1995 Jun;47(2):331-85
pubmed: 7568331
J Med Chem. 2014 Aug 14;57(15):6332-41
pubmed: 24967612
Am J Physiol Endocrinol Metab. 2013 Feb 1;304(3):E237-53
pubmed: 23211518
Arzneimittelforschung. 1953 Jun;3(6):285-90
pubmed: 13081480
Expert Opin Investig Drugs. 2018 Jan;27(1):17-30
pubmed: 29216787
J Biopharm Stat. 2012;22(3):535-43
pubmed: 22416839
Cancer Res. 2019 Sep 1;79(17):4539-4550
pubmed: 31142512
Nucleic Acids Res. 2019 Jul 2;47(W1):W43-W51
pubmed: 31066443
BMC Bioinformatics. 2011 Jan 26;12:35
pubmed: 21269502
Pharm Stat. 2013 May-Jun;12(3):115-9
pubmed: 23471653
Cancer Res. 2020 Jun 1;80(11):2286-2297
pubmed: 32152150
Int J Clin Exp Pathol. 2014 Oct 15;7(11):8096-104
pubmed: 25550857

Auteurs

Licai Huang (L)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Quantitative Sciences Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, 77030, USA.

Jing Wang (J)

Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Bingliang Fang (B)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Funda Meric-Bernstam (F)

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Jack A Roth (JA)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Min Jin Ha (MJ)

Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, South Korea. mjha@yuhs.ac.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH